PressMay 11, 2022 MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
PressMay 10, 2022 Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
PressMay 5, 2022 PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
PressMay 4, 2022 Nova Mentis Psilocybin Manufacturer Receives Approved Health Canada Importation Permit
PressMay 3, 2022 COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
PressMay 2, 2022 Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
PressApril 29, 2022 Allied Corp Announces Purchase Order Continuing into Monthly Supply Agreement for Brazilian Specialty Cancer Care Hospital
PressApril 26, 2022 Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
PressApril 25, 2022 Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its DMT and 5-MeO-DMT Drug Candidate Compounds
PressApril 22, 2022 Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
PressApril 21, 2022 Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
PressApril 20, 2022 Nue Life Health, a Next-Gen Mental Wellness Platform, Announces a $23M Financing Led by Obvious Ventures and Western Technology Investment
PressApril 19, 2022 Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
PressApril 18, 2022 Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
PressApril 15, 2022 NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows
PressApril 14, 2022 Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
PressApril 13, 2022 Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds
PressApril 12, 2022 Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
PressApril 11, 2022 Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
PressApril 8, 2022 Homecoming Closes $4 Million Seed Funding Round To Scale Psychedelic Therapy Companion Tools
